EW stock forecast, quote, news & analysis
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease... Show more
Why Edwards Lifesciences (EW) Is Down -1.8% in the Last 30 Days
Key Takeaways
- EW stock declined -1.8% over the past 30 days amid volatile trading and valuation pressures following a mid-March peak.
- Over the past quarter, shares fell -4.9%, reflecting profit-taking and a Q4 earnings miss on earnings per share (EPS).
- Strong Q4 sales growth of 11.6% provided some support, but high price-to-earnings (PE) ratio of 44.75 fueled concerns.
- Analyst upgrades, including a recent Buy rating with a $92 target, offer potential uplift.
- Upcoming Q1 earnings and structural heart demand trends are key factors influencing sentiment.
Edwards Lifesciences (EW) Company Overview and Market Position
Edwards Lifesciences Corporation (EW) is a global leader in patient-focused innovations for structural heart disease and critical care monitoring. The company develops and manufactures medical devices, including transcatheter aortic valve replacement (TAVR) systems, surgical heart valves, and hemodynamic monitoring technologies. Its core business model centers on advancing minimally invasive treatments for heart conditions, driving growth through product innovation and expanding adoption in high-volume procedures.
In the competitive medical device industry, EW holds a dominant position in the structural heart segment, benefiting from a strong portfolio and clinical data superiority. These fundamentals underpin its stock behavior, as investor focus remains on procedural growth and reimbursement dynamics, though elevated valuations expose it to sentiment shifts.
Edwards Lifesciences (EW) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, EW stock decreased -1.8%, moving from approximately $82.50 to $80.99. The price action was volatile and range-bound, peaking near recent highs before retreating amid choppy trading.
In the past quarter, shares dropped -4.9%, from around $85.14 to $80.99. The movement featured sharp swings, including a mid-March high of $87.18 followed by a pullback, characteristic of trend-driven volatility influenced by earnings reactions and sector rotation.
What Drove EW Stock Price in the Last 30 Days
The modest 30-day decline stemmed primarily from profit-taking after a March peak, coupled with broader market rotation away from high-growth healthcare stocks. Valuation concerns intensified, with EW's PE ratio exceeding 44x trailing earnings, prompting selectivity among investors.
Company-specific factors included insider selling by a vice president in early April, which added short-term pressure. Positive offsets came from analyst actions, such as Wolfe Research's upgrade to Buy with a $92 price target, signaling confidence in structural heart momentum. Sector sentiment remained mixed, with medtech peers facing similar headwinds from macroeconomic caution around interest rates and healthcare spending.
What Drove EW Stock Performance Over the Last Quarter
The quarterly downturn was driven by a Q4 earnings report in February that beat sales expectations at $1.57 billion (up 11.6% year-over-year) but missed EPS consensus at $0.58 versus $0.62 expected. This triggered an initial sell-off, amplifying volatility as investors reassessed growth sustainability.
Broader industry developments, including competitive pressures in TAVR and reimbursement uncertainties, contributed to the slide. Macroeconomic conditions, such as persistent inflation and elevated interest rates, weighed on growth-oriented medtech valuations. Institutional positioning showed rotation toward value sectors, with EW's high beta to market trends exacerbating the -4.9% move. Despite this, the company's refined focus post-critical care divestiture bolstered long-term narratives around core structural heart exposure.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing and most relevant AI-driven trading bots from its extensive library of hundreds of bots actively trading thousands of tickers across various markets. These bots employ diverse strategies, including trend-following, mean reversion, and momentum-based approaches, tailored to different timeframes from intraday to long-term holds. Performance metrics such as win rate, average return, and Sharpe ratio highlight standout performers, helping traders identify tools aligned with their risk tolerance and market views. Updated in real-time, the curated selection reflects current market conditions and bot efficacy. Explore Trending AI Robots to discover bots potentially suited for stocks like EW.
EW Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming Q1 earnings for updates on TAVR volumes, procedural growth, and 2026 guidance. Industry trends in structural heart devices, including new product launches and clinical trial outcomes, could sway sentiment.
The macro environment, encompassing interest rate paths, healthcare policy changes, and reimbursement decisions, remains critical. Strategic developments like partnerships or regulatory approvals for next-generation valves warrant attention. Key risks include intensified competition from peers and potential shifts in hospital spending, alongside catalysts from analyst revisions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Momentum Indicator for EW turns positive, indicating new upward trend
EW saw its Momentum Indicator move above the 0 level on June 23, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for EW just turned positive on June 24, 2026. Looking at past instances where EW's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EW advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 243 cases where EW Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EW declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
EW broke above its upper Bollinger Band on July 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. EW’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.789) is normal, around the industry mean (10.756). P/E Ratio (46.422) is within average values for comparable stocks, (61.593). Projected Growth (PEG Ratio) (2.063) is also within normal values, averaging (3.713). EW has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (7.955) is also within normal values, averaging (23.791).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of products to treat late-stage cardiovascular disease
Industry MedicalNursingServices